CORT
Corcept Therapeutics Incorporated
72.80$
+1.6%
vs. previous close
Closing price · As of: Nov 6, 2026
Ownership
Ownership Structure
Who owns Corcept Therapeutics Incorporated (CORT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 89.3% of the shares are freely tradable; institutional investors hold 75.7%.
Institutional ownership
?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
75.7%
Insiders
?Share of the stock held by the executives, founders and major shareholders of the company itself.
11.5%
Float
?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
89.3%
Short % of float
?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
10.1%
Shares Outstanding
?Total number of shares issued. Price times share count gives market cap.
109Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 11.50 | 12,432,023 | +2.3 | 06/30/2026 |
| Ingalls & Snyder LLC | 7.34 | 7,934,507 | +4.3 | 06/30/2026 |
| Renaissance Technologies Corp | 4.87 | 5,261,628 | -7.4 | 06/30/2026 |
| Vanguard Portfolio Management, LLC | 4.67 | 5,044,638 | +4.6 | 06/30/2026 |
| Vanguard Capital Management, LLC | 3.86 | 4,172,482 | +2.3 | 06/30/2026 |
| Parallel Advisors, LLC | 3.67 | 3,962,177 | -0.4 | 06/30/2026 |
| FMR Inc | 3.09 | 3,337,618 | +4.6 | 06/30/2026 |
| State Street Corp | 3.03 | 3,279,381 | +2.5 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 3.16 | 3,417,684 | +0.1 | 10/29/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.86 | 3,091,208 | +6.6 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Mahoney David L | Director | 1,133,539 | 82,521,639 $ | Aug 18, 2026 | indirect |
| Wilson James N | Director | 1,054,543 | 76,770,730 $ | Oct 15, 2026 | indirect |
| Robb Gary Charles | Chief Business Officer | 74,343 | 5,412,170 $ | Aug 17, 2026 | both |
| Mokari Atabak | Chief Financial Officer | 16,304 | 1,186,931 $ | Sep 2, 2026 | direct |
| Maduck Sean | See Remarks | 9,938 | 723,486 $ | Nov 3, 2026 | direct |
| Lyon Joseph Douglas | See Remarks | 5,683 | 413,722 $ | Oct 2, 2026 | direct |
| Guyer William | Chief Development Officer | 4,313 | 313,986 $ | Sep 1, 2026 | direct |
| Vieira Roberto Wandenkolk | President, Oncology | 3,946 | 287,269 $ | Nov 2, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | Maduck Sean | See Remarks | Sell | 4,542 | 82.68 | 375,513 |
| Nov 3, 2026 | Maduck Sean | See Remarks | Sell | 8,617 | 82.02 | 706,765 |
| Nov 3, 2026 | Maduck Sean | See Remarks | Other | 13,159 | 8.27 | 108,825 |
| Nov 2, 2026 | Maduck Sean | See Remarks | Sell | 11,841 | 81.42 | 964,074 |
| Nov 2, 2026 | Maduck Sean | See Remarks | Other | 11,841 | 8.27 | 97,925 |
| Nov 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 1,676 | 81.52 | 136,632 |
| Nov 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 6,657 | 80.73 | 537,437 |
| Nov 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Other | 8,333 | 21.63 | 180,243 |
| Oct 15, 2026 | Wilson James N | Director | Sell | 300 | 116.30 | 34,889 |
| Oct 15, 2026 | Wilson James N | Director | Sell | 3,046 | 115.39 | 351,476 |
| Oct 15, 2026 | Wilson James N | Director | Sell | 6,654 | 114.48 | 761,717 |
| Oct 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 5,147 | 116.59 | 600,063 |
| Oct 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 2,086 | 115.73 | 241,412 |
| Oct 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 1,100 | 114.52 | 125,973 |
| Oct 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Other | 8,333 | 21.63 | 180,243 |
| Oct 2, 2026 | Lyon Joseph Douglas | See Remarks | Sell | 4,744 | 116.54 | 552,869 |
| Oct 2, 2026 | Lyon Joseph Douglas | See Remarks | Sell | 4,446 | 115.70 | 514,389 |
| Oct 2, 2026 | Lyon Joseph Douglas | See Remarks | Other | 5,833 | 19.26 | 112,344 |
| Oct 2, 2026 | Lyon Joseph Douglas | See Remarks | Other | 3,357 | 13.56 | 45,521 |
| Oct 2, 2026 | Maduck Sean | See Remarks | Sell | 8,744 | 116.55 | 1,019,143 |
| Oct 2, 2026 | Maduck Sean | See Remarks | Sell | 15,843 | 116.12 | 1,839,741 |
| Oct 2, 2026 | Maduck Sean | See Remarks | Other | 24,587 | 8.27 | 203,334 |
| Oct 1, 2026 | Lyon Joseph Douglas | See Remarks | Sell | 810 | 115.40 | 93,473 |
| Oct 1, 2026 | Lyon Joseph Douglas | See Remarks | Other | 810 | 13.56 | 10,984 |
| Oct 1, 2026 | Maduck Sean | See Remarks | Sell | 413 | 115.54 | 47,717 |
| Oct 1, 2026 | Maduck Sean | See Remarks | Other | 413 | 8.27 | 3,416 |
| Sep 24, 2026 | Robb Gary Charles | Chief Business Officer | Other | 5,000 | 0.00 | – |
| Sep 24, 2026 | Robb Gary Charles | Chief Business Officer | Other | 17,100 | 0.00 | – |
| Sep 17, 2026 | Robb Gary Charles | Chief Business Officer | Other | 17,493 | 8.27 | 144,667 |
| Sep 16, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 296 | 100.82 | 29,843 |
| Sep 15, 2026 | Wilson James N | Director | Sell | 2,800 | 111.70 | 312,771 |
| Sep 15, 2026 | Wilson James N | Director | Sell | 400 | 110.84 | 44,335 |
| Sep 15, 2026 | Wilson James N | Director | Sell | 6,800 | 110.27 | 749,835 |
| Sep 14, 2026 | Lyon Joseph Douglas | See Remarks | Sell | 2,188 | 114.12 | 249,686 |
| Sep 14, 2026 | Lyon Joseph Douglas | See Remarks | Sell | 7,812 | 113.32 | 885,261 |
| Sep 14, 2026 | Lyon Joseph Douglas | See Remarks | Other | 7,404 | 13.56 | 100,398 |
| Sep 14, 2026 | Lyon Joseph Douglas | See Remarks | Other | 2,596 | 11.35 | 29,465 |
| Sep 2, 2026 | Maduck Sean | See Remarks | Other | 117 | 113.38 | 13,265 |
| Sep 2, 2026 | Mokari Atabak | Chief Financial Officer | Other | 102 | 113.38 | 11,565 |
| Sep 2, 2026 | Robb Gary Charles | Chief Business Officer | Other | 91 | 113.38 | 10,318 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 1,225 | 115.44 | 141,413 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 5,621 | 114.58 | 644,042 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 1,606 | 113.72 | 182,632 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 974 | 112.40 | 109,474 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 1,537 | 111.37 | 171,181 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 23,770 | 110.70 | 2,631,349 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 23,600 | 109.35 | 2,580,674 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Other | 58,333 | 21.63 | 1,261,743 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Other | 102 | 113.38 | 11,565 |
| Sep 2, 2026 | Lyon Joseph Douglas | See Remarks | Other | 72 | 113.38 | 8,163 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.